Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,253
archived clinical trials in
Arthritis

A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis
A Phase Ib, Open-Label, Multicenter Study to Investigate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab Following Subcutaneous Administration to Patients With Systemic Juvenile Idiopathic Arthritis
Status: Enrolling
Updated:  11/16/2017
Levine Children's Hospital; Divison of Pediatric Rheumatology; Department of Pediatrics
mi
from
Charlotte, NC
A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis
A Phase Ib, Open-Label, Multicenter Study to Investigate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab Following Subcutaneous Administration to Patients With Systemic Juvenile Idiopathic Arthritis
Status: Enrolling
Updated: 11/16/2017
Levine Children's Hospital; Divison of Pediatric Rheumatology; Department of Pediatrics
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis
A Phase Ib, Open-Label, Multicenter Study to Investigate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab Following Subcutaneous Administration to Patients With Systemic Juvenile Idiopathic Arthritis
Status: Enrolling
Updated:  11/16/2017
Duke University
mi
from
Durham, NC
A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis
A Phase Ib, Open-Label, Multicenter Study to Investigate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab Following Subcutaneous Administration to Patients With Systemic Juvenile Idiopathic Arthritis
Status: Enrolling
Updated: 11/16/2017
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis
A Phase Ib, Open-Label, Multicenter Study to Investigate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab Following Subcutaneous Administration to Patients With Systemic Juvenile Idiopathic Arthritis
Status: Enrolling
Updated:  11/16/2017
Cincinnati Children'S Hospital Medical Center; Division of Rheumatology
mi
from
Cincinnati, OH
A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis
A Phase Ib, Open-Label, Multicenter Study to Investigate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab Following Subcutaneous Administration to Patients With Systemic Juvenile Idiopathic Arthritis
Status: Enrolling
Updated: 11/16/2017
Cincinnati Children'S Hospital Medical Center; Division of Rheumatology
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis
A Phase Ib, Open-Label, Multicenter Study to Investigate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab Following Subcutaneous Administration to Patients With Systemic Juvenile Idiopathic Arthritis
Status: Enrolling
Updated:  11/16/2017
Cleveland Clinic Fndn
mi
from
Cleveland, OH
A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis
A Phase Ib, Open-Label, Multicenter Study to Investigate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab Following Subcutaneous Administration to Patients With Systemic Juvenile Idiopathic Arthritis
Status: Enrolling
Updated: 11/16/2017
Cleveland Clinic Fndn
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis
A Phase Ib, Open-Label, Multicenter Study to Investigate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab Following Subcutaneous Administration to Patients With Systemic Juvenile Idiopathic Arthritis
Status: Enrolling
Updated:  11/16/2017
University of Utah; Immunology/Rheumatology/Allergy
mi
from
Salt Lake City, UT
A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis
A Phase Ib, Open-Label, Multicenter Study to Investigate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab Following Subcutaneous Administration to Patients With Systemic Juvenile Idiopathic Arthritis
Status: Enrolling
Updated: 11/16/2017
University of Utah; Immunology/Rheumatology/Allergy
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis
A Phase Ib, Open-Label, Multicenter Study to Investigate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab Following Subcutaneous Administration to Patients With Systemic Juvenile Idiopathic Arthritis
Status: Enrolling
Updated:  11/16/2017
Seattle Children's Hospital
mi
from
Seattle, WA
A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis
A Phase Ib, Open-Label, Multicenter Study to Investigate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab Following Subcutaneous Administration to Patients With Systemic Juvenile Idiopathic Arthritis
Status: Enrolling
Updated: 11/16/2017
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis
A Phase Ib, Open-Label, Multicenter Study to Investigate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab Following Subcutaneous Administration to Patients With Systemic Juvenile Idiopathic Arthritis
Status: Enrolling
Updated:  11/16/2017
Hospital Gral de Niños Pedro Elizalde
mi
from
Buenos Aires,
A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis
A Phase Ib, Open-Label, Multicenter Study to Investigate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab Following Subcutaneous Administration to Patients With Systemic Juvenile Idiopathic Arthritis
Status: Enrolling
Updated: 11/16/2017
Hospital Gral de Niños Pedro Elizalde
mi
from
Buenos Aires,
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Rheumatology Associates, PC
mi
from
Birmingham, AL
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Rheumatology Associates, PC
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Arizona Arthritis and Rheumatology Research
mi
from
Glendale, AZ
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Arizona Arthritis and Rheumatology Research
mi
from
Glendale, AZ
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Arizona Arthritis & Rheumatology Associates, P. C.
mi
from
Mesa, AZ
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Arizona Arthritis & Rheumatology Associates, P. C.
mi
from
Mesa, AZ
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Arizona Arthritis Research PLC
mi
from
Phoenix, AZ
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Arizona Arthritis Research PLC
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Little Rock Diagnostic Clinic
mi
from
Little Rock, AR
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Little Rock Diagnostic Clinic
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
The University of California, San Diego
mi
from
La Jolla, CA
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
The University of California, San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Purushotham & Akther Kotha MD Inc
mi
from
LA Mesa, CA
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Purushotham & Akther Kotha MD Inc
mi
from
LA Mesa, CA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Stanford University Hospital
mi
from
Palo Alto, CA
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Stanford University Hospital
mi
from
Palo Alto, CA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
East Bay Rheumatology Medical Group, Inc.
mi
from
San Leandro, CA
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
East Bay Rheumatology Medical Group, Inc.
mi
from
San Leandro, CA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Office: Dr Robin K Dore
mi
from
Tustin, CA
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Office: Dr Robin K Dore
mi
from
Tustin, CA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Rheumatology Associates of South Florida
mi
from
Boca Raton, FL
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Rheumatology Associates of South Florida
mi
from
Boca Raton, FL
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Jeffrey Alper, MD Research
mi
from
Naples, FL
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Jeffrey Alper, MD Research
mi
from
Naples, FL
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Arthritis & osteoporosis treatment center,PA
mi
from
Orange Park, FL
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Arthritis & osteoporosis treatment center,PA
mi
from
Orange Park, FL
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Gulf Clinical Research Institute
mi
from
Pensacola, FL
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Gulf Clinical Research Institute
mi
from
Pensacola, FL
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Diagnostic Rheumatology and Research PC
mi
from
Indianapolis, IN
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Diagnostic Rheumatology and Research PC
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Physician's Clinic of Iowa, P.C.
mi
from
Cedar Rapids, IA
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Physician's Clinic of Iowa, P.C.
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Heartland Research Associates, LLC
mi
from
Wichita, KA
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Heartland Research Associates, LLC
mi
from
Wichita, KA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Bluegrass Community Research, Inc
mi
from
Lexington, KY
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Bluegrass Community Research, Inc
mi
from
Lexington, KY
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Johns Hopkins Arthritis Center
mi
from
Baltimore, MD
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Johns Hopkins Arthritis Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Klein & Associates, MD, PA
mi
from
Cumberland, MD
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Klein & Associates, MD, PA
mi
from
Cumberland, MD
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Klein & Associates MD, PA.
mi
from
Hagerstown, MD
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Klein & Associates MD, PA.
mi
from
Hagerstown, MD
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Tufts Medical Center
mi
from
Boston, MA
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Beals Institute
mi
from
Lansing, MI
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Beals Institute
mi
from
Lansing, MI
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
North MS Medical Clinics, Inc.
mi
from
Tupelo, MS
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
North MS Medical Clinics, Inc.
mi
from
Tupelo, MS
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Washington University Medical Center
mi
from
Saint Louis, MO
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Washington University Medical Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Glacier View Research Institute
mi
from
Kalispell, MT
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Glacier View Research Institute
mi
from
Kalispell, MT
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Physician Research Collaboration
mi
from
Lincoln, NE
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Physician Research Collaboration
mi
from
Lincoln, NE
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
New Jersey Physicians, LLC
mi
from
Clifton, NJ
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
New Jersey Physicians, LLC
mi
from
Clifton, NJ
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Atlantic Coastal Research
mi
from
Toms River, NJ
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Atlantic Coastal Research
mi
from
Toms River, NJ
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Arthritis, Rheumatic & Back Disease Associates
mi
from
Voorhees, NJ
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Arthritis, Rheumatic & Back Disease Associates
mi
from
Voorhees, NJ
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Albuquerque Rehabilitation & Rheumatology, PC
mi
from
Albuquerque, NM
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Albuquerque Rehabilitation & Rheumatology, PC
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Center for Rheumatology
mi
from
Albany, NY
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Center for Rheumatology
mi
from
Albany, NY
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Weill Cornell Medical College
mi
from
Brooklyn, NY
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Weill Cornell Medical College
mi
from
Brooklyn, NY
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Allergy Asthma Immunology of Rochester, AAIR Research Ctr
mi
from
Rochester, NY
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Allergy Asthma Immunology of Rochester, AAIR Research Ctr
mi
from
Rochester, NY
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Rheumatology Associates of Long Island
mi
from
Smithtown, NY
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Rheumatology Associates of Long Island
mi
from
Smithtown, NY
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Arthritis and Osteoporosis Consultants of the Carolinas
mi
from
Charlotte, NC
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Arthritis and Osteoporosis Consultants of the Carolinas
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Box Arthritis and Rheumatology of the Carolina's
mi
from
Charlotte, NC
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Box Arthritis and Rheumatology of the Carolina's
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
PMG Research of Hickory, LLC
mi
from
Hickory, NC
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
PMG Research of Hickory, LLC
mi
from
Hickory, NC
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
MetroHealth Med Ctr
mi
from
Cleveland, OH
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
STAT Research, Inc.
mi
from
Dayton, OH
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
STAT Research, Inc.
mi
from
Dayton, OH
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Health Research Institute
mi
from
Oklahoma City, OK
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Health Research Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Oregon Health and Science University
mi
from
Portland, OR
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials